PLA2R1 and membranous glomerulonephritis: A 2024 case-series of 18 patients with PLA2R-associated membranous nephropathy demonstrated either partial or complete remission in 94.4% of patients, 61.1% of whom had unsatisfactory response to Rituximab, with a median time to remission of 2.7 months [13].